Cellectar biosciences broadens pipeline with targeted alpha therapy (tat) for solid tumors and releases promising preclinical data

Proprietary tat phospholipid conjugate demonstrates potent activity in resistant pancreatic cancer initiating ind-enabling studies for first-in-human phase i clinical study florham park, n.j., jan. 16, 2024 (globe newswire) -- cellectar biosciences, inc. (nasdaq: clrb), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced promising preclinical data for its proprietary novel alpha-emitting phospholipid radiotherapeutic conjugate, clr 121225 (225ac-clr 121225) an actinium-labeled phospholipid ether (ple), in pancreatic cancer models.
CLRB Ratings Summary
CLRB Quant Ranking